On February 12, the official website of China’s State Drug Administration released the news about “conditional approval for the import registration of Pfizer’s new coronavirus treatment drug nematovir tablet/ritonavir tablet combination package (i.e. Paxlovid)”, which was a sensation for a while. “Can the new coronavirus drug really be an effective treatment? Is the epidemic almost over? Is the drug expensive? Is it available for everyone?” And so on, similar questions abounded. So is this special medicine really that good? Perhaps you can find out after reading the following.